^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    iNeo-Vac-P01

    i
    Associations
    News

    Trials

    Company:
    Hangzhou Neoantigen Therap
    Drug class:
    Immunostimulant
    Related drugs:
    Associations
    News

    Trials

    Apply
    Clinical Study of a Personalized Neoantigen Cancer Vaccine Combined With Anti-PD-1 and RFA in Patients With Solid Tumors (NCT04864379)
    Phase 1
    Sir Run Run Shaw Hospital
    Recruiting
    Last update posted :
    04/28/2021
    Initiation :
    09/03/2020
    Primary completion :
    08/03/2025
    Completion :
    08/03/2025
    CD8 • IFNG • CD4
    |
    iNeo-Vac-P01